Jejunal Luminal and Colonic Mucosa-Associated Microbiota in Metabolic Diseases: Methods, Identification and Causalities
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Metagenomic analysis
研究概览
简要总结
This clinical study will investigate Jejunal Microbiota in Metabolic Diseases (Je-MiMe, n=45) and Colonic mucosa-associated Microbiota in Metabolic Diseases (Col-MiMe, n=45).
Each cohort (Je and Col -MiMe) is composed of three groups: participants with obesity (n=15) with obesity and with type II diabetes (n=15).
This research protocol is organized in two parts. Each part of this study will recruit 45 participants that are only recruited in one of the parts of the protocol (JE-MIME or COL-MIME). Thus, in total, the study will include 90 patients. Each part of this study is composed of 3 groups: 1) "Control Group ", 2) Obese group (Ob), 3) Obese and Type 2 Diabetes group (ObD). Control groups for part I (JE-MIME) and part 2 (COL-MIME) are composed of different participants. Each group is composed of 15 human adult volunteers for the JE-MIME study (part 1) and 15 participants for the COL-MIME study (part 2). Total number of participants is 45 for part 1, and 45 for part 2. Total number for this project is 90.
Microbiota wil be collected during an endoscopy or coloscopy which is planned as routine care for the patients.
Primary objectives are to characterize jejunal (JE-MIME, Part I of the study) and colonic mucosa-associated microbiota (COLMIME, Part II of the study) and compare both microbiota to faecal microbiota (evaluate differences and similarities between jejunal microbiota or mucus-associated microbiota and faecal microbiota).
Secondary objectives are to 1) Correlate microbiota with metabolic health and inflammatory markers; 2) Correlate microbiota with lifestyle and neuropsychological health.
Both the jejunal microbiota and mucus-associated microbiota are strong integrators of nutritional environment and intestinal health status, respectively, compared to the fecal microbiota. This study will help to better understand the physiopathology of metabolic diseases. This research could lead to finding specific microbiota members, either from the jejunal compartment or from the inner mucus layer, crucial for the promotion / protection of chronic intestinal inflammation and associated metabolic health.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •General Inclusion Criteria:
- •Aged between 18 and 60 years;
- •Ability to understand and provide informed consent (in French);
- •Ability and willingness to meet the required schedule and study procedures;
- •Group-Specific Inclusion Criteria:
- •Control Group
- •Inclusion criteria for the participants from the Control group are:
- •Presence of Gastroesophageal Reflux Disease symptoms or gastric discomfort.
- •BMI [19kg/m² < BMI <25 kg/m²]
- •Match age and sex to the patients from the Ob and ObD groups.
- •Only patients with normal glucose tolerance (NGT), glucose tolerance (IGT) and/or fasting glucose (IFG) and an HbA1c < 6.5 % will be included in this group.
- •Inclusion criteria for the participants from Ob and ObD groups are:
- •● Candidate for bariatric surgery and meet the HAS criteria (Haute Autorité de Santé, 2009) :
- •IMC ≥ 40 kg/m² without comorbidities Or IMC≥ 35 kg/m² with at least one obesity-related comorbidity (i.e.: Hypertension, Dyslipidemia, Obstructive Sleep Apnea, Joints Disease, non-alcoholic steatohepatitis, excluding T2D)
- •Weight stable for at least 2 months
- •No treatment for metabolic health complications, no previous obesity surgery, no obesity treatment drug.
- •No monogenic form of obesity (Hebebrand et al., 2017)
- •ObD Group
- •Inclusion criteria for the participants from ObD groups are:
- •Candidate for bariatric surgery with T2D
- •At least one obesity-related comorbidity including T2D
- •Fasting plasma glucose (FPG) ≥7 mM (=1.26g/l) or
- •Participants with HbA1c ≥ 6.5% (48 mmol/mol)
- •All stages of albuminuria
排除标准
- •General Non-inclusion Criteria:
- •Treatment for the previous 12 week that could
- •alter gastrointestinal motor function (e.g. opioids, prokinetics, anticholinergics, laxatives),
- •acidity (PPI, H2RA)
- •microbial population (e.g.: antibiotics, probiotics)
- •immunosuppressants (eg: calcineurin inhibitors, corticosteroids, biological agents, etc.).
- •use of weight-loss drug or dietary intervention aiming to lose weight;
- •Altered anatomy of the esophagus, stomach, small or large intestine due to prior gastrointestinal surgery (exceptions include appendectomy or cholecystectomy more than 3 months prior to enrollment) or other reasons;
- •Any abdominal or pelvic surgery within the past 3 months;
- •Diverticulitis, diverticular stricture, or other intestinal strictures.
- •Intestinal resection of the gastrointestinal tract
- •Previous history of gastric bezoar or gastroparesis
- •Acute or chronic inflammatory bowel disease or infections diseases (i.e.: VHC, VHB, VIH, etc.)
- •Abdominal or pelvic radiotherapy or abdominal cancer
- •Colorectal cancer, either known or not
- •Dysphagia, eosinophilic esophagitis, esophageal stricture, or other swallowing disorder
- •Organ Transplantation and patients on Immunosuppressive Therapy
- •Severe kidney failure and/or patients on dialysis therapy (serum creatinine > 150 μmol/l or eGFR < 60 ml/min per 1.73 m2 body surface area)
- •CVD, endocrine, renal or other chronic disease likely to affect motility.
- •Colon cleansing preparation during the last 1 month
- •No < 3 bowel movements per week
- •Females of childbearing age who do not practice birth control and/or are pregnant or lactating
- •Participants non-affiliated to the French national health scheme
- •Participants who are already included in a clinical study which implies testing any pharmaceutical drug.
- •Participants who do not understand the research procedures those who are institutionalized, or who unable to give informed consent
- •Participants placed under legal protection
- •Patients with drug addiction
- •Antibiotherapy 3 months preceding the endoscopy
- •Weight variation (diminution or increase) > 5kg in the last 3 months
- •Specific non-inclusion Criteria
- •Ob and ObT2D Group
- •Usual contraindication for bariatric surgery;
结局指标
主要结局
Metagenomic analysis
时间窗: 1 month
Single time point analysis of jejunal or colonic mucosal-associated and fecal microbiota. Microbiota will be analysed through 16S rRNA gene sequencing as well as shotgun metagenomic sequencing of the different samples. We will examine if jejunal microbiota abundance is decreased in subjects with obesity and obesity + type 2 diabetics compared to lean subjects. Based on metagenomic sequencing data, the number of bacterial genes will be estimated and compared between groups. We will examine the distance of bacterial layer in the mucus from intestinal epithelial cells in people with T2D as compared to people without T2D and lean subjects.
次要结局
- Clinical associations with metagenomic analysis(1 month)